The H63D variant in the HFE gene predisposes to arthralgia, chondrocalcinosis and osteoarthritis

B Z Alizadeh, O T Njajou, J M W Hazes, A Hofman, P E Slagboom, H A P Pols and C M van Duijn

Ann Rheum Dis 2007;66;1436-1442; originally published online 6 Feb 2007; doi:10.1136/ard.2006.063099

Updated information and services can be found at:
http://ard.bmj.com/cgi/content/full/66/11/1436

These include:

References
This article cites 36 articles, 13 of which can be accessed free at:
http://ard.bmj.com/cgi/content/full/66/11/1436#BIBL

Rapid responses
You can respond to this article at:
http://ard.bmj.com/cgi/eletter-submit/66/11/1436

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to Annals of the Rheumatic Diseases go to:
http://journals.bmj.com/subscriptions/
The H63D variant in the HFE gene predisposes to arthralgia, chondrocalcinosis and osteoarthritis

B Z Alizadeh, O T Njajou, J M W Hazes, A Hofman, P E Slagboom, H A P Pols, C M van Duijn


OBJECTIVES: To investigate the relation between the HFE C282Y and H63D variants with arthralgia and joint pathology in the population-based Rotterdam Study.

METHODS: From a cohort of 7983 people aged 55 years and over, 2095 randomly drawn subjects were genotyped for C282Y and H63D variants. We compared the frequency of arthralgia, and the presence of chondrocalcinosis, osteophytes, joint space narrowing and radiographic osteoarthritis in hand, hip and knee joints, and Heberden’s nodes in carriers of HFE variants with that in non-carriers.

RESULTS: Overall, there was a significantly higher frequency of arthralgia (odds ratio 1.6; 95% CI 1.0 to 2.6), oligoarthritis (2.3; 1.2 to 4.4) and Heberden’s nodes (2.0; 1.1 to 3.8) in H63D homozygotes compared with non-carriers. In subjects aged 65 years or younger, H63D homozygotes had significantly more often polyarthritis (3.1; 1.3 to 7.4), chondrocalcinosis in hip or knee joints (4.7; 1.2 to 18.3), and more hand joints with osteophytes (6.1 ± 0.1 vs. 4.4 ± 0.3), space narrowing (2.8 ± 0.5 vs. 1.0 ± 0.1), radiographic osteoarthritis (4.4 ± 0.7 vs. 2.0 ± 0.2) and Heberden’s nodes (3.1; 1.3 to 12.8) than non-carriers. We found no relation of arthralgia or joint pathology to C282Y, but compound heterozygotes had a significantly higher frequency of arthralgia (2.9; 1.0 to 9.3), chondrocalcinosis in hip joints (6.5; 1.8 to 22.3), and an increased number of osteophytes in knee (6.9 ± 1.2, n = 5 vs. 2.4 ± 0.1) joints at a later age (>65 years).

CONCLUSIONS: The HFE H63D variant may explain, at least in part, the prevalence of arthralgia in multiple joint sites, chondrocalcinosis, and hand osteoarthritis in the general population.

arthropathy affects up to 85% of patients with type I hereditary haemochromatosis, seriously influencing their quality of life. Hand, hip and knee joints are most often affected. In patients with haemochromatosis, arthropathy may originate from a progressive degenerative arthritis initially presenting in hand joints, but it can also originate from an inflammatory mediated condition like chondrocalcinosis, or it may resemble rheumatoid arthritis, accompanied by Heberden’s nodes. The main radiographic findings in haemochromatosis arthropathy are calcium crystal deposits, osteophytes and joint space narrowing.

The HFE C282Y and H63D variants are the most common genetic factors involved in hereditary haemochromatosis. Eleven per cent of Caucasians are carriers of C282Y, and 23% of the total population worldwide are carriers of H63D. The risk of haemochromatosis is increased for C282Y homozygotes (4383-fold) or compound heterozygotes, that is carriers of both H63D and C282Y (32-fold). Also, H63D homozygotes are estimated to have a sixfold increased risk of haemochromatosis, although their iron levels may be modestly increased.

Findings on the relation between HFE variants and arthropathy are neither consistent nor conclusive. Some studies found no relationship between C282Y and self-reported arthropathy, inflamed joints, chondrocalcinosis or subchondral arthropathy. Other studies reported a significant association between C282Y and chondrocalcinosis, or late-onset hand osteoarthritis. Few studies have addressed the role of H63D. Most studies on the HFE gene variants were based on clinical samples, and were prone to selection bias. Thus, the generalisability of these studies has been a matter of concern.

We have studied the HFE C282Y and H63D variants in the population-based Rotterdam Study. The variants were studied in relation to arthralgia as well as joint pathology assessed from radiographs, including chondrocalcinosis in hip or knee joints, presence of osteophytes, joint space narrowing, radiographic osteoarthritis in hand, hip or knee joints, and Heberden’s nodes. We also investigated the relationship between HFE, arthralgia and overall mortality.

METHODS

Population

This study was performed in the framework of the Rotterdam Study, a population-based cohort study of major chronic diseases in a large city in the Netherlands. The medical ethics committee of the Erasmus Medical Centre approved the study, and informed consent was obtained from all participants. The design and objectives of the study have been described elsewhere. In brief, the study population consists of 7983 inhabitants aged 55 years or over living in the district of Ommoord in Rotterdam. Baseline examinations took place between 1990 and 1993 by means of a structured interview using a standardised questionnaire. In the Rotterdam Study, all participants have been followed since 1990, with information on the vital status of participants being obtained at regular intervals from municipal health authorities in Rotterdam. The data on hospital admissions and a corresponding diagnosis of haemochromatosis were retrieved from interviews with participants and from their general practitioners’ medical records. Data on the disease conditions and mortality were available for all the participants. From the total cohort, 2095 randomly drawn subjects were genotyped for the HFE C282Y and H63D variants.

Main outcome measures

In this study, the main outcome measures included arthralgia and osteoarthritis in hand, hip and knee joints at baseline examination between 1990 and 1993. At the baseline examination, participants were asked whether they had any pain in or around their joints. If yes, the study physicians questioned participants about the site and duration of joint complaints.
and asked whether they had received a medical diagnosis of joint or other diseases, or whether they were treated with any kind of pain medication or physiotherapy because of their joint complaints. At the study's research centre, study physicians examined the hands of all participants for the presence of Heberden's nodes, a common local form of osteoarthritis in the distal interphalangeal joints with inflammatory episodes that are associated with generalised osteoarthritis. Within the randomly selected cohort (n = 2095), clinical data were available on the presence or absence of arthralgia for 2047 subjects and on Heberden's nodes for 1833 subjects.

The baseline anteroposterior radiographs of hip and knee joints of a random subset of the population were scored for the presence of chondrocalcinosis and radiographic osteoarthritis by two independent medical physicians who were trained by a musculoskeletal radiologist and a rheumatologist (J H); they were also blind to all information on participants as explained elsewhere. The reliability of scoring for radiographic osteoarthritis in hip or knee joints has been explained elsewhere. In brief, whenever the scores of the two assessors differed by more than one grade or when one assessor scored grade 1 and the other grade 2 or higher, one more consensus reading was carried out that was later confirmed by the musculoskeletal radiologist.

The presence of osteophytes and space narrowing in the baseline anteroposterior and lateral oblique radiographs of hands were assessed in the distal and proximal interphalangeal joints, the interphalangeal joint of thumb, the metacarpophalangeal joints, the first carpometacarpal joints and the trapeziocapitate joints. Osteophytes were differentiated into three grades (small, moderate and large), while joint space narrowing was scored as either present or absent. Lateral deformity was defined as misalignment of at least 15°. Radiographic osteoarthritis in hand, hip and knee joints was graded (0–4) as proposed by Kellgren and Lawrence using the Radiographic osteoarthritis in hand, hip and knee joints was considered for any joint with a Kellgren–Lawrence score of two or higher. The two assessors both independently scored a random subset of 205 radiographs for osteoarthritis in hand joints. The inter-observer reliability for Kellgren–Lawrence scores of the two assessors, expressed by kappa statistics, was as follows: DIP 0.60, PIPs 0.61, MCPs 0.63; and CMC1/TS 0.74. Within the randomly selected cohort, there were data available on the presence of chondrocalcinosis in hip or knee joints for 1112 subjects, and in hip joints for 1352 subjects. Finally, for H63D or C282Y homozygotes (n = 65), all radiographs at baseline and follow-up were re-examined for the presence of osteophytes, joint space narrowing, sclerosis, cyst formation, calcification, chondrocalcinosis in subchondral bone in hand, hip and knee joints and in spinal joints for disk degeneration, spondylophytes and calcification by a rheumatologist (JH) who was blind to the clinical data but knew of the subjects' HFE genotypes.

Blood samples were collected on the day of baseline examination by venepuncture. The HFE C282Y and H63D variants were genotyped as described elsewhere.

Data analysis
The extent of arthralgia was categorised into 4 groups: 0 for no arthralgia (the reference group), 1 for presence of pain in one, 2 for pain in two (oligoarthralgia), and 3 for pain in three or more (polyarthralgia) joint sites. The presence of osteophytes, space narrowing and radiographic osteoarthritis in hands joints was transformed to 3 independent quantitative traits by summing the number of joints with the corresponding condition. The HFE C282Y genotypes were modelled by assigning a value of 0, 1 or 2 for carriers of no (non-carriers), one (C282Y heterozygotes), or two (C282Y homozygotes) copies of this variant, respectively. The same procedure was done for H63D. Genotype proportions were tested for Hardy–Weinberg equilibrium. Independent t statistics, ANOVA and χ² tests were used for comparisons of means and frequencies. We performed cross-sectional analyses to estimate odds ratio with 95% confidence interval (95% CI). We used logistic regression analysis to test the association of C282Y or H63D with the risk of arthralgia overall and in different joint sites, chondrocalcinosis in hip or knee joints, or Heberden's nodes in both hands, and radiographic osteoarthritis in hip or knee joints. Univariate regression analysis was used to estimate the adjusted mean with the standard errors for the number of hand joints with osteophytes, joint space narrowing, or radiographic osteoarthritis by the HFE genotypes. For the study of mortality, we used a Cox proportional regression analysis. All analyses were adjusted for age and gender. Since a relation of C282Y heterozygosity to hand osteoarthritis was found in patients older than 65 years, and since there may be differences in the aetiopathogenesis of early- and late-onset arthropathy, we stratified our analysis by age using a cutoff point of 65 years. A two-sided p<0.05 was considered statistically significant.

RESULTS
Baseline characteristics
Table 1 presents the baseline characteristics of the participants. Subjects with arthralgia were more often female and users of pain medications (p<0.001). Genotype frequencies and baseline characteristics did not differ between those aged 65 years or younger and those older than 65 years, or between subjects who had data on genotype, clinical and radiographic findings compared with others (data not shown). In subjects with arthralgia, the number of painful joints for each person ranged from 1 to 10 (median = 2). Allele and genotype proportions were in Hardy–Weinberg equilibrium overall and also in those without arthralgia. The baseline characteristics did not differ across the HFE genotypes, except that H63D homozygotes aged 65 years or younger were significantly more often users of pain medications and physiotherapy than non-carriers (data not shown).

HFE variants and arthralgia
Overall, H63D homozygotes had a significantly higher frequency of arthralgia (OR 1.6; 95% CI 1.0 to 2.6; p = 0.05) and oligoarthralgia (2.3; 1.2 to 4.4; p = 0.01) compared with non-carriers. The frequency of arthralgia was not higher in C282Y or H63D heterozygotes compared with non-carriers. Figure 1 presents the analysis stratified by age. H63D homozygotes aged 65 years or younger had arthralgia significantly (p = 0.01) more often than non-carriers. Figure 2A shows that H63D homozygotes had a significantly increased risk of arthralgia in hands (p = 0.006), in hips (p = 0.05) and in knees (p = 0.03). In those older than 65 years, the frequency of arthralgia did not differ by HFE genotypes (figs 1 and 2B).

HFE variants and chondrocalcinosis
Overall, there was no significant difference in the frequency of chondrocalcinosis in hip or knee joints in the HFE genotypes. When stratifying by age (table 2), H63D homozygotes aged 65 years or younger had a significantly (p = 0.02) higher frequency of chondrocalcinosis compared with non-carriers.

HFE variants and radiographic osteoarthritis
Overall, the number of joints with osteophytes in the hands increased significantly with the numbers of H63D variant (for
trend, p<0.01). Among subjects aged 65 years or younger, the number of joints with osteophytes was higher in H63D heterozygotes (p = 0.03) or homozygotes (p = 0.08) than in non-carriers (for trend, p = 0.03; table 3).

H63D homozygotes had a significantly increased number of hand joints with space narrowing, or radiographic osteoarthritis compared with non-carriers in subjects aged 65 years or younger. Again, no relation to HFE genotypes was found in subjects older than 65 years. We found no significant difference in the number of osteophytes, presence of space narrowing or radiographic osteoarthritis across HFE genotypes in either hip or knee joints (data not shown).

HFE variants and Heberden’s nodes

Overall, 21.5% of H63D homozygotes (n = 51) compared with 16.9% of non-carriers (n = 1316) had Heberden’s nodes (OR 2.1; 95% CI 1.1 to 3.9; p = 0.02). Again, H63D homozygotes aged 65 years or younger had a significantly (p = 0.02) higher frequency of Heberden’s nodes compared with non-carriers (table 4).

Compound heterozygotes and outcomes

Compound heterozygotes aged 65 years or younger were associated with none of the outcomes studied. Compound heterozygotes older than 65 years had a significantly higher frequency of polyarthralgia (2.9; 1.0 to 9.3; p = 0.05), and hip chondrocalcinosis (6.5; 1.8 to 22.3; p = 0.001) compared with non-carriers and had significantly more osteophytes in knee joints in the overall analysis (4.9 (0.6) vs 2.2 (0.1); p = 0.01) and in those older than 65 years (6.9 (1.2), n = 5 vs 2.4 (0.1), n = 374; p = 0.01). In hands, none of the outcomes studied showed any difference between compound heterozygotes and non-carriers in subjects older than 65 years.

HFE variants, arthralgia and mortality

To explore why we found a strong relation of H63D homozygosity to arthralgia and arthropathy before age 65 years but not later in life, we studied the mortality in H63D homozygotes with arthralgia. In subjects aged 65 years or younger, H63D homozygotes with arthralgia were found to have a fourfold (95% CI 1.4 to 11.7; p<0.01) higher risk of mortality than non-carriers without arthralgia during the study’s follow-up period.

C282Y or H63D homozygotes and clinical arthropathy

When the rheumatologist (JH) re-examined the radiographs of all the C282Y (n = 6) or H63D (n = 59) homozygotes, most of the subjects had two or more joints affected with multiple pathologies such as osteophytes, sclerosis, joint space narrowing...
and calcification. The clinical findings with regard to the features that we did not discuss earlier are summarised in table 5. In reassessing the x-rays of C282Y and H63D homozygotes for a clinical diagnosis, the rheumatologist (J H) was aware of the genotype, so an overestimation of clinical outcomes in this group is possible. Nevertheless, in only 3 subjects (3/65, 4.6%) were the radiographic findings recognised as compatible with hereditary haemochromatosis. Of the C282Y homozygotes, 3 subjects younger than 65 years had osteoarthritis in hands, and 1 of these had one total hip replacement. Of the other 2, 1 had mild generalised osteoarthritis, and another had a moderate spondylophytosis.

**HFE variants and clinical haemochromatosis**

None of the C282Y or H63D homozygotes, or compound heterozygotes, had received a diagnosis of clinical haemochromatosis from their general practitioner or any other physician at the baseline or during the follow-up study period.

**DISCUSSION**

**Principal findings**

This study evaluated the relationship between HFE and arthropathy in the general population. Overall, we found that H63D homozygotes had arthralgia more often. In subjects aged 65 years or younger, H63D homozygosity was consistently associated with arthralgia in multiple joint sites, chondrocalcinosis, radiographic osteoarthritis in hands and Heberden’s nodes. H63D homozygotes used pain medication more often. In subjects with arthralgia who were 65 years or younger at the baseline examination, H63D homozygotes had a strong and consistent increased risk of early-onset arthralgia and arthropathy in multiple joint sites. In line with this finding, H63D homozygotes used pain medication more often in our study population. We found no relation to arthropathy in C282Y homozygotes or heterozygotes. The effect of C282Y on iron metabolism is stronger than that of H63D, 24, 34 and so the risk for haemochromatosis is the highest.15 Thus, one might expect a stronger association with arthropathy in C282Y carriers. There may be a number of explanations for why we failed to observe any association. One may speculate that the numbers of C282Y homozygotes were too few to draw any definite conclusion in our study. However, this lack of association is not unique to our population. Others have also found no relation to arthralgia or joint pathology in carriers of C282Y.19–20 One of these studies comprises over 40 000 persons who were screened for HFE and showed no relation of arthralgia to C282Y homozygosity.

**Advantages and limitations of this study**

A point of concern for population-based studies of genetic factors is the probability of bias due to population admixture.31, 32 Typing of multiple genetic markers as suggested by Pritchard and Rosenberg33 has not revealed any evidence for the presence of population admixture in the Rotterdam Study. Another source of bias may be observer-related misclassification. All our radiographs were scored blind to other clinical data and genotyping. Further, any systematic loss to follow-up or missing data are unrelated to participants’ HFE genotypes or osteoarthritis profile. Therefore, the occurrence of spurious associations due to population admixture or a selective misclassification is unlikely. The major strengths of our study are its population-based design, the large number of participants and the use of several related clinical and radiographic outcomes.

**C282Y, H63D and arthropathy**

We observed that H63D homozygotes had a strong and consistent increased risk of early-onset arthralgia and arthropathy in multiple joint sites. In line with this finding, H63D homozygotes used pain medication more often in our study population. We found no relation to arthropathy in C282Y homozygotes or heterozygotes. The effect of C282Y on iron metabolism is stronger than that of H63D, 24, 34 and so the risk for haemochromatosis is the highest.15 Thus, one might expect a stronger association with arthropathy in C282Y carriers. There may be a number of explanations for why we failed to observe any association. One may speculate that the numbers of C282Y homozygotes were too few to draw any definite conclusion in our study. However, this lack of association is not unique to our population. Others have also found no relation to arthralgia or joint pathology in carriers of C282Y.19–20 One of these studies comprises over 40 000 persons who were screened for HFE and showed no relation of arthralgia to C282Y homozygosity.
uncommon in other forms of iron-storage diseases, suggesting an effect on arthropathy. In this respect, the significantly higher mortality in a subgroup of H63D homozygotes aged 65 years or younger is of concern. Furthermore, the early mortality may explain why the association of H63D homozygosity to arthropathy is stronger early in life but absent later on. Further studies are needed, to translate our findings into clinical and public health practice.

| Table 3 | Number of hand joints with osteophytes, joint space narrowing or radiographic osteoarthritis (ROA) by HFE genotypes† |
|-----------------------------------------------|
| HFE genotypes | Osteophytes | Joint space narrowing | ROA‡ |
|                | <65 years | >65 years | <65 years | >65 years | <65 years | >65 years |
| C282Y Non-carriers | 590 | 5.0±0.3 | 353 | 6.3±0.4 | 1.4±0.1 | 1.6±0.2 | 2.4±0.5 | 3.3±0.4 |
| Heterozygotes | 78 | 5.5±0.6 | 71 | 5.8±0.7 | 1.9±0.3 | 1.2±0.4 | 2.3±0.4 | 2.6±0.6 |
| Homozygotes | 3 | 5.3±2.5 | 3 | 2.3±4.9 | 0.2±1.5 | 2.3±3.0 | 3.6±4.2 | |
| H63D Non-carriers | 466 | 4.4±0.3 | 446 | 4.7±1.6 | 1.0±0.1 | 2.0±1.0 | 2.0±0.2 | 3.5±1.4 |
| Heterozygotes | 184 | 5.2±0.4 | 142 | 4.7±1.7 | 1.2±0.2 | 1.6±1.0 | 2.4±0.3 | 3.2±1.4 |
| Homozygotes | 18 | 6.1±1.0 | 18 | 4.9±2.0 | 2.8±0.5** | 1.5±1.2 | 4.4±0.7** | 2.8±1.7 |

* p<0.03, † p<0.01 for comparison with non-carriers; ‡ figures are means ± standard errors, calculated using univariate linear regression analysis after adjustment for age and gender. n, number of subjects.

(n=128) or compound heterozygosity (n=616). Together, these findings suggest that C282Y is not a determinant of arthralgia in the general population. When considering the relation between C282Y and joint pathologies, two studies reported a weak relation of C282Y to chondrocalcinosis, and another study reported a relation between C282Y heterozygosity and late-onset hand osteoarthritis. For C282Y heterozygosity, we found an effect on arthralgia and arthropathy only in compound heterozygotes for C282Y and H63D older than 65 years, suggesting that C282Y heterozygosity may have a late effect on arthropathy.

From a pathological prospect, this raises the question as to whether levels of iron determine the relation between H63D and early-onset arthropathy. In fact, iron overload may not be the main determinant of arthropathy, as it shows a poor response to phlebotomy, and arthropathy did not show any relation to iron concentration in the liver or to levels of serum iron or ferritin in our population (data not shown). Moreover, arthropathy can occur with moderate iron overload and is uncommon in other forms of iron-storage diseases, suggesting the arthropathy may not be explained directly by iron overload. Further research is needed to determine the mechanism by which H63D affects the risk of arthropathy. The report on the relation between H63D and rheumatoid arthritis, the consistent relation of H63D to polyarthralgia, Heberden’s nodes, chondrocalcinosis and early-onset hand osteoarthritis, which are all partially inflammatory mediated conditions, suggests that an alternative mechanism may be responsible. An understanding of the underlying aetiopathogenesis may provide new targets for intervention in haemochromatotic arthropathy.

| Table 4 | Frequency of Heberden’s nodes by HFE genotypes† |
|-----------------------------------------------|
| HFE genotypes | Age <65 years | Odds ratio (95% CI) | Age >65 years | Odds ratio (95% CI) |
|                | n | Percent | | n | Percent | |
| Heterozygotes | 701 | 19.7 | 1.0 (reference) | 835 | 19.2 | 1.0 (reference) |
| Homozygotes | 107 | 15.0 | 0.9 (0.5 to 1.7) | 110 | 11.8 | 0.6 (0.3 to 1.0) |
| H63D Non-carriers | 2 | 50.0 | 4.0 (0.2 to 65.3) | 2 | 0.0 | – |
| Heterozygotes | 637 | 16.0 | 1.0 (reference) | 726 | 17.9 | 1.0 (reference) |
| Homozygotes | 246 | 16.3 | 1.0 (0.7 to 1.6) | 240 | 19.6 | 1.1 (0.7 to 1.6) |

*p<0.02 for comparison with non-carriers; † OR, odds ratios compare the frequency of Heberden’s nodes among subjects heterozygous or homozygous for the C282Y or H63D variants to that of non-carriers, calculated using logistic regression analysis after adjustment for age and gender. CI, confidence interval. n, number of subjects.

Clinical implications
In this study, H63D homozygosity was found to be associated with arthropathy. Earlier, we have shown that H63D homozygotes in the same study population had higher levels of serum iron and ferritin. However, none of the H63D homozygotes had a clinical diagnosis of haemochromatosis, or of diabetes mellitus or liver pathology, two diseases associated with haemochromatosis. This suggests that carriers of H63D may present initially with only arthropathy, perhaps together with excess iron. Thus, they may remain undiagnosed and therefore untreated for hereditary haemochromatosis. If left untreated, the disease may progress to irreversible complications like liver diseases or to cerebro-cardiovascular events like stroke, leading to early death. In this respect, the significantly higher mortality in a subgroup of H63D homozygotes with arthralgia aged 65 years or younger is of concern. Furthermore, the early mortality may explain why the association of H63D homozygosity to arthropathy is stronger early in life but absent later on. Further studies are needed, to translate our findings into clinical and public health practice.

Conclusion
Taken together, our findings suggest that H63D may explain at least some of the early-onset arthropathy in the general population. Although this conclusion needs to be confirmed by others, we consider it may well be clinically relevant to test patients with arthralgia who are younger than 65 years for HFE variants.

ACKNOWLEDGEMENTS
The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam, the Netherlands Organization for
Table 5 Radiographic findings (%) in subjects homozygous for the HFE C282Y or H63D variants*  

<table>
<thead>
<tr>
<th>Radiographic findings</th>
<th>Age &lt;65 years</th>
<th>Age &gt;65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hips</td>
<td>Knees</td>
</tr>
<tr>
<td>C282Y homozygotes (n=6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spondylophytes</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Articular or peri-articular calcifications</td>
<td>33.3</td>
<td>33.3</td>
</tr>
<tr>
<td>Subchondral bony sclerosis</td>
<td>33.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Subchondral bony cysts</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>H63D homozygotes (n=59)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spondylophytes</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Articular or peri-articular calcifications</td>
<td>20.0</td>
<td>16.0</td>
</tr>
<tr>
<td>Subchondral bony sclerosis</td>
<td>16.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Subchondral bony cysts</td>
<td>8.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

*Figures are percentages. n, number of subjects.

Authors’ affiliations
B Z Alizadeh, O T Njajou, A Hofman, C M van Duijn, Department of Epidemiology & Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands
J M W Hazes, Department of Rheumatology and Department of Epidemiology & Biostatistics Erasmus Medical Centre, Rotterdam, The Netherlands
P E Slagboom, Department of Molecular Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
H A P Pols, Department of Internal Medicine, and Department of Epidemiology & Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands

Competing interests: None declared.

REFERENCES
BMJ Clinical Evidence — Call for contributors

BMJ Clinical Evidence is a continuously updated evidence-based journal available worldwide on the internet which publishes commissioned systematic reviews. BMJ Clinical Evidence needs to recruit new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine, with the ability to write in a concise and structured way and relevant clinical expertise.

Areas for which we are currently seeking contributors:
- Secondary prevention of ischaemic cardiac events
- Acute myocardial infarction
- MRSA (treatment)
- Bacterial conjunctivitis

However, we are always looking for contributors, so do not let this list discourage you.

Being a contributor involves:
- Selecting from a validated, screened search (performed by in-house Information Specialists) valid studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we will publish.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with BMJ Clinical Evidence editors to ensure that the final text meets quality and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The BMJ Clinical Evidence in-house team will conduct the searches for contributors; your task is to filter out high quality studies and incorporate them into the existing text.
- To expand the review to include a new question about once every 12 months.

In return, contributors will see their work published in a highly-rewarded peer-reviewed international medical journal. They also receive a small honorarium for their efforts.

If you would like to become a contributor for BMJ Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

BMJ Clinical Evidence also needs to recruit new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific reviews within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Reviews are usually 1500–3000 words in length and we would ask you to review between 2–5 systematic reviews per year. The peer review process takes place throughout the year, and our turnaround time for each review is 10–14 days. In return peer reviewers receive free access to BMJ Clinical Evidence for 3 months for each review.

If you are interested in becoming a peer reviewer for BMJ Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp